Spectrum to Present Five Zevalin Study Abstracts at ASCO Meeting

Spectrum Pharmaceuticals will be presenting five study abstracts related to Zevalin, the company's radioimmunotherapeutic antibody regimen for indolent B-cell non-Hodgkin's lymphomas, at the annual meeting of the American Society of Clinical Oncology in Chicago during the first weekend in June 2012:

-- Effect of short-duration chemoimmunotherapy plus radioimmunotherapy on response rates in relapsed follicular lymphoma: A U.K. NCRI Lymphoma Group Study.

-- Effect of radioimmunotherapy-based conditioning for autologous stem cell transplantation on poor-risk molecular profiling in diffuse large B-cell lymphoma.

-- A phase II trial 90y-ibritumomab tiuxetan [Zevalin] in combination with reduced intensity regimen of fludarabine (flu) and melphalan (mel) followed by allo-HCT in patients with refractory B-cell lymphoma.

-- Phase II study of short CHOP-rituximab combination with early consolidation with ibritumomab-tiuxetan-Y90 (IT-Y90) in non-pretreated patients age 65 to 80 with CD20+ diffuse large B-cell lymphoma (DLBCL).

-- Minimum tolerable interval of 90yttrium ibritumomab-tiuxetan to autologous stem cell transplantation after high-dose chemotherapy with carmustin, etoposide, cytarabine, and melphalan for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.

Zevalin is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). It is also indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma who achieve a partial or complete response to first-line chemotherapy.

Source: ASCO abstracts